To announce the FDA approval of linaclotide for pediatric patients aged 2 years and older with functional constipation.
Key Findings:
Functional constipation affects approximately 3% of preschool-aged children.
Linaclotide is the only FDA-approved prescription therapy for pediatric functional constipation.
Diarrhea was the most commonly reported adverse reaction in clinical trials.
Interpretation:
The approval provides an FDA-approved treatment option for managing functional constipation in young children, which can be challenging with over-the-counter therapies.
Limitations:
Linaclotide is contraindicated in patients younger than 2 years due to the risk of serious dehydration.
Conclusion:
The availability of linaclotide may support a more tailored therapeutic approach for children aged 2-5 years.
